162 related articles for article (PubMed ID: 15134556)
21. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
23. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
Stringer KA
Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
[TBL] [Abstract][Full Text] [Related]
24. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
25. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
Vorchheimer DA; Fuster V
Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
[No Abstract] [Full Text] [Related]
26. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
27. Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
Malhotra S; Mishra NK; Sinha RS; Gupta B
J Assoc Physicians India; 2000 Mar; 48(3):329-34. PubMed ID: 11229122
[TBL] [Abstract][Full Text] [Related]
28. A perspective on the toxicological mechanisms possibly contributing to the failure of oral glycoprotein IIb/IIIa antagonists in the clinic.
Sy SK; Levenstadt AL
Am J Cardiovasc Drugs; 2004; 4(1):1-10. PubMed ID: 14967061
[TBL] [Abstract][Full Text] [Related]
29. Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Van de Werf F
Thromb Haemost; 1997 Jul; 78(1):210-3. PubMed ID: 9198155
[TBL] [Abstract][Full Text] [Related]
30. Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: Part 2: When and how to use various agents.
Zimarino M; De Caterina R
J Cardiovasc Pharmacol; 2004 Apr; 43(4):477-84. PubMed ID: 15085057
[TBL] [Abstract][Full Text] [Related]
31. Anti-GPIIb/IIIa drugs: current strategies and future directions.
Coller BS
Thromb Haemost; 2001 Jul; 86(1):427-43. PubMed ID: 11487034
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
Konstantopoulos K; Mousa SA
Curr Opin Investig Drugs; 2001 Aug; 2(8):1086-92. PubMed ID: 11892918
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
Cannon CP; McCabe CH; Borzak S; Henry TD; Tischler MD; Mueller HS; Feldman R; Palmeri ST; Ault K; Hamilton SA; Rothman JM; Novotny WF; Braunwald E
Circulation; 1998 Feb; 97(4):340-9. PubMed ID: 9468207
[TBL] [Abstract][Full Text] [Related]
34. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Tcheng JE
Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
[TBL] [Abstract][Full Text] [Related]
35. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
36. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
37. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
Armstrong PC; Peter K
Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
[TBL] [Abstract][Full Text] [Related]
38. Prospective use of glycoprotein IIb/IIIa receptor blockers in the emergency department setting.
Gibler WB; Wilcox RG; Bode C; Castaigne AD; Delooz H; Elich D; Fox KA; Kereiakes DJ; Rupprecht H; Topol EJ
Ann Emerg Med; 1998 Dec; 32(6):712-22. PubMed ID: 9832669
[TBL] [Abstract][Full Text] [Related]
39. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Atwater BD; Roe MT; Mahaffey KW
Drugs; 2005; 65(3):313-24. PubMed ID: 15669877
[TBL] [Abstract][Full Text] [Related]
40. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.
Roffi M; Chew DP; Mukherjee D; Bhatt DL; White JA; Heeschen C; Hamm CW; Moliterno DJ; Califf RM; White HD; Kleiman NS; Théroux P; Topol EJ
Circulation; 2001 Dec; 104(23):2767-71. PubMed ID: 11733392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
